News

Persistent’s PaxPro Brand Asset Lifecycle Management solution is a secure, policy-based solution designed to review and approve all media content within complex packaging and branding workflows. It offers

Modufolin is anticipated to increase the efficacy and reduce the side effects of cytotoxic pharmaceuticals. The approval allows Isofol Medical to start its first clinical trial on humans,

Under the agreement, JHP Pharma will be responsible for manufacturing and supply of an approved therapy used in cancer patients. JHP Pharma manufactures sterile injectables, biologics, vaccines, ophthalmics

ENB-0040 is a bone targeted enzyme replacement therapy designed to directly target TNSALP to the bone in order to correct the enzyme deficiency, which could result in restoration

Pfizer has already paid $200m to Biocon, as part of the agreement signed between them in October 2010, to get access to the supply of four generic insulin

The company has posted a net income of $20.8m for the fourth quarter of 2010, compared to $47.42m for the same period in 2009. Mylan has earned gross

XIFAXAN is indicated for the treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating. Rifaximin is a gut-selective antibiotic with negligible systemic absorption and broad-spectrum activity

BioSante Pharma is developing LibiGel as a treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women. The efficacy trials are being conducted

The success could help make TRO40303 the first treatment to reduce cardiac reperfusion injury which leads to morbidity and mortality myocardial infarction. The study was aimed at assessing